Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × Letrozole × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Intraductal, Noninfiltrating 3 Ovarian Neoplasms 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostatic Neoplasms 1 Polycystic Ovary Syndrome 1 Pathologic Complete Response 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Low Grade Serous Ovarian Cancer 1 Locoregional Recurrence 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Head and Neck Neoplasms 1 HR+/HER2- Breast Cancer 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Anatomic Stage III Breast Cancer AJCC v8 1 Advanced Unresectable or Metastatic Breast Cancer of Adults 1 Advanced Breast Carcinoma 1 Advanced Breast Cancer 1

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡